Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DNASTAR Releases Lasergene 12 Software

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Lasergene 12 improves sequence alignments and NGS accuracy.

DNASTAR® has announced the release of Lasergene 12, highlighting significant improvements in MegAlign Pro, a multiple sequence alignment application within Lasergene®, and industry-leading accuracy in NGS reference-guided assembly and SNP calling.

Additionally, the release features new, easy-to-use workflows designed for clinical researchers who analyze panels of genes, leveraging human exome or whole human genome data.

MegAlign Pro was initially released as part of Lasergene in the spring of 2013. Improvements to MegAlign Pro included in Lasergene 12 are the MAFFT alignment algorithm, several new analysis and visualization methods, and enhanced phylogenetic tree capability.

The Lasergene Genomics Suite has been dramatically improved in Lasergene 12, with SNP calling accuracy at 99.8% and the introduction of a series of new gene panel workflows. These enhancements will support clinical researchers by integrating VCF and BED (or Manifest) files for Mendelian/Germline and Cancer/Somatic investigations. The Lasergene Genomics Suite has also been enhanced to support SNP validation and control, which many clinical researchers find invaluable to their work.

Tom Schwei, Vice President and General Manager of DNASTAR, said, “DNASTAR has been delivering software to meet the needs in the molecular biology general research software market for the past 30 years. With Lasergene 12, we have continued to enhance our general research offering, while also putting a heavy emphasis on supporting the emerging needs of clinical researchers using Next-Generation Sequencing (NGS) data. The enhancements to MegAlign Pro and improved accuracy of our NGS assembler and SNP caller will serve all markets well, while the gene panel workflows are aimed at serving the clinical research market, which includes many of DNASTAR’s current customers. We are very pleased to continue to meet the needs of a wide range of molecular biologists and other life scientists. We look forward to continuing to broaden our appeal to researchers involved in genomics and related fields through future software releases and updates.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Wellcome Trust Sanger Institute Adopts DNASTAR Lasergene Software
Wellcome Trust Sanger Institute and DNASTAR have entered into a multi-year software license agreement.
Thursday, December 05, 2013
DMNB Adopts DNASTAR Lasergene Software
New Lasergene software site license agreement for genome sequence assembly and analysis.
Thursday, September 05, 2013
DNASTAR Awarded Antibody Engineering SBIR Grant
NIH awarded grant to build antibody engineering software.
Tuesday, May 15, 2012
DNASTAR Partners with Ion Torrent
Ion Torrent offers DNASTAR’s sequence assembly and analysis software products to the customers through the Ion Torrent on-line web store in the collaboration.
Wednesday, February 16, 2011
DNASTAR Joins BioIT Alliance
BioIT Alliance announces the expansion of the BioIT Alliance program to include DNASTAR.
Thursday, January 28, 2010
DNASTAR and the University of Iowa Sign Lasergene Site License Agreement
Researchers on the University of Iowa campus have gained unlimited access and use of the software for their sequence analysis projects.
Wednesday, January 06, 2010
Wageningen University and DNASTAR Extend Lasergene Site License Agreement
Under the terms of the site license, researchers will have unlimited use of the software for their sequence analysis projects.
Tuesday, November 24, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be pair with a precision therapy.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!